Location of attacks
|
All
|
Women
|
no prophylaxis vs. Danazol
|
Men
|
no prophylaxis vs. Danazol
|
women vs. men
|
---|
All
|
No prophylaxis
|
Danazol
|
p-values
|
All
|
No prophylaxis
|
Danazol
|
p-values
|
p-values
|
---|
|
104
|
57
|
31
|
13
| |
47
|
28
|
13
| | |
abdomen
|
68 (65 %)
|
40 (70 %)
|
24 (77 %)
|
6 (46 %)
|
p = 0.042
|
28 (59 %)
|
15 (53 %)
|
9 (69 %)
|
p = 0.344
|
p = 0.063
|
extremities
|
61 (59 %)
|
34 (60 %)
|
20 (64 %)
|
5 (38 %)
|
p = 0.111
|
27 (57 %)
|
14 (50 %)
|
8 (61 %)
|
p = 0.491
|
p = 0.157
|
trunk
|
22 (21 %)
|
15 (26 %)
|
8 (26 %)
|
3 (10 %)
|
p = 0.849*
|
7 (15 %)
|
4 (14 %)
|
0
|
p = 0.288*
|
p = 0.523*
|
face
|
22 (21 %)
|
14 (24 %)
|
8 (26 %)
|
2 (6 %)
|
p = 0.697*
|
8 (17 %)
|
4 (14 %)
|
1 (8 %)
|
p = 0.486**
|
p = 0.709**
|
genitals
|
22 (21 %)
|
11 (19 %)
|
8 (26 %)
|
1 (3 %)
|
p = 0.242*
|
11 (23 %)
|
5 (18 %)
|
3 (23 %)
|
p = 0.692*
|
p = 0.586*
|
headache
|
16 (15 %)
|
11 (19 %)
|
4 (13 %)
|
3 (10 %)
|
p = 0.404*
|
5 (11 %)
|
4 (14 %)
|
0
|
p = 0.288*
|
p = 0.509*
|
larynx
|
16 (15 %)
|
9 (16 %)
|
6 (19 %)
|
1 (3 %)
|
p = 0.654
|
7 (15 %)
|
4 (14 %)
|
1 (8 %)
|
p = 0.486**
|
p = 0.700**
|
- * Fisher’s exact test, ** one-sided
- Number of patients who suffered from at least one attack in the individual location in 2012